Inclusion Criteria:

Both HIV infected and HIV uninfected individuals are eligible for this study.

• CD4 cell count of 400 cells/mm3 or greater at study entry
• If HIV infected, initiated anti-HIV medicines within 120 days of infection
• If HIV infected, HIV viral load < 50 copies/ml for at least 3 months prior to study entry
• Current medication regimen for at least 3 months prior to study entry
• A particular blood type (HLA-A*0201)
• Acceptable methods of contraception

Exclusion Criteria:

• Received investigational drug or vaccine within 30 days prior to study entry
• On other immune-based therapy (e.g., interleukin-2, alpha interferon, immunoglobulin, thalidomide) within 30 days prior to study entry
• Megesterol acetate within 30 days prior to study entry
• Immunization within 4 weeks of study entry
• If hepatitis B virus (HBV) uninfected and at high risk for HBV infection, the patient will not be eligible until he or she has completed an HBV vaccine series.
• Unstable or severe medical condition, including active opportunistic infection requiring treatment
• History of Hashimoto's thyroiditis
• Cancer requiring chemotherapy within 6 months prior to study entry
• History of radiation therapy to axillary lymph nodes
• Significant laboratory abnormalities at study entry
• Pregnant or breastfeeding
• History of autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, autoimmune hepatitis, scleroderma, mixed connective tissue disorder)
• Allergy to gentamicin, tobramycin, streptomycin, or amikacin